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Abstract 
The normal mammary gland and invasive breast cancer are both complex ‘organs’ 
composed of multiple cell types as well as extracellular matrix (ECM) in three-
dimensional (3D) space. Conventionally, both normal and malignant breast cells are 
studied in vitro as two-dimensional (2D) monolayers of epithelial cells, which results 
in the loss of structure and tissue function. Many laboratories are now investigating 
regulation of signaling function in normal mammary gland using 3D cultures. 
However, it is important also to assay malignant breast cells ex vivo in a 
physiologically relevant environment to more closely mimic tumor architecture, 
signal transduction regulation and tumor behavior in vivo. Here we present the 
potential of these 3D models for drug testing, target validation and guidance of patient 
selection for clinical trials. We argue also that in order to get full insight into the 
biology of the normal and malignant breast, and to create in vivo-like models for 
therapeutic approaches in humans, we need to continue to create more complex 
heterotypic models to approach the full context the cells encounter in the human body.  
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1. Introduction 
It is now becoming increasingly clear that cancer is not a single disease and that it is 
organ- and tissue-specific. Further, even within a single organ, such as the mammary 
gland, tumors are heterogeneous with respect to histology, gene expression and 
clinical outcome. In order to advance our understanding of the complex biology of 
breast cancer and eventually to improve clinical management of the disease, we need 
experimental model systems that recapitulate the in vivo functions, interactions and 
architecture of the mammary gland and breast tumors.  
The mammary gland, like many glandular organs, is embedded in stroma, which is 
composed of mesenchymal cells, such as fibroblasts, adipocytes, immune cells and 
extracellular matrix (ECM). Our laboratory postulated long ago that the ECM not only 
provides structural support but also signaling cues via transmembrane receptors, 
directing cytoskeletal and chromatin organization to maintain tissue integrity [1,2]. 
More than two decades ago, it was shown that collagen gels, which provide a 3D 
scaffold, allow epithelial cells of various tissues and origins to maintain some of their 
tissue structure and differentiated functions [3-6]. Building on these first observations, 
we developed 3D culture systems using either collagen gels [7,8] or, more importantly 
for epithelial cells, laminin-rich extracellular matrices (lrECM) to study tissue-
specific functions of normal mouse mammary cells [9,10] as well as normal and  
malignant human cells [11]. In parallel with our experiments, others developed 
cultures for rat hepatocytes [12]. Since then, the in vivo-like properties provided by 
the 3D model systems has received broader appreciation and has been adopted for the 
study of diverse tissues and cells besides mammary luminal epithelial cells and 
hepatocytes such as skin [13,14], muscle [15], colon [16], bile duct [17], esophagus 
[18], as well as adipocytes [19], fibroblasts [20,21] and embryonic stem cells [22,23] 
among others. 
 
In this review, we first depict how 3D cell culture models can be utilized to dissect 
signaling pathways that regulate function of normal and malignant mammary 
epithelial structures. We further describe the potential of these models for applied 
breast cancer research, namely the identification of prognostic and predictive profiles 
and therapeutic screening. Second, we discuss the future challenges we will have to 
face in order to bring the understanding of breast cancer and its treatment to full 
fruition.  
 
 2. The normal mammary gland and breast cancer 
The normal human mammary gland consists of a branching ductal-lobular system. 
The lobules of the human breast are organized into 15-20 lobes which are drained by a 
collecting duct that converge at the nipple in a radial arrangement [24]. Each lobule in 
turn is made up of acini (also called alveoli) that form the functional secretory units of 
the mammary gland, the terminal duct lobular units (TDLUs). The acini and ducts 
have a central lumen and are lined by two cell layers, an inner layer of polarized 
luminal epithelial cells and an outer layer of myoepithelial cells both of which are 
surrounded by a basement membrane (BM) separating them from the stroma (Fig. 
1A). The latter is composed of varying amounts of fat, connective tissue, blood 
vessels, nerves, and lymphatics [24].  
Almost all breast malignancies arise in the TDLU, regardless of the histological type 
of the tumor [25,26]. In general, carcinomas are characterized by the loss of epithelial 
polarity and tissue organization. Breast cancer cells that remain within the BM of the 
mammary ductal-lobular system are classified as in situ carcinomas. Once neoplastic 
cells rupture the BM and invade into the adjacent stroma, the tumor has become 
invasive (Fig. 1A). Remarkably, invasive breast carcinomas exhibit a wide range of 
morphological types, molecular profiles and clinical behaviors [26]. The clinical 
heterogeneity of the disease is reflected by the fact that metastases can occur at all 
stages of disease and over a long period of 10 years or more after initial diagnosis 
[27,28]. Histologically, invasive breast cancers are categorized into at least 19 
different subtypes based on growth patterns and cytonuclear characteristics of the 
tumor cells [26]. A number of these histological subtypes show particular prognostic 
and clinical characteristics [26,29]. Aside from morphology, breast cancers are 
divided also into two major groups based on whether or not the tumor cells express 
the nuclear estrogen receptor-α (ER). In clinical practice, the ER status is used to 
predict the response to adjuvant anti-estrogen therapies, such as tamoxifen [30].  
The analysis of gene expression using DNA microarrays led to a new breast cancer 
classification. Within the group of ER-negative breast carcinomas, three distinct 
molecular subtypes (basal-like, HER2+ and normal breast-like) have been identified 
on the basis of their RNA molecular profiling. The ER-positive tumors could be 
subdivided into two subtypes (luminal A and luminal B)[31,32]. Recent work 
 
suggests that the intensively studied ‘basal-like’ tumors are not a homogeneous group 
but again comprise a large phenotypic and prognostic spectrum [33,34]. The gene 
expression analyses done over the past years highlight the complexity of the disease at 
molecular level, which might not be entirely surprising considering the histological 
and structural complexity of breast carcinomas. Besides cancer cells, invasive breast 
tumors comprise stromal cells, such as fibroblasts and immune cells, and ECM. 
Remarkably, the amount and composition of stromal cells and ECM varies greatly 
among tumors [26,29], a finding that has clinical importance. Invasive breast 
carcinomas could be classified based on the expression of ECM components, and 
these ECM classes were associated with survival and recurrence risk [35]. The 
specific characteristics of the breast cancer stroma may harbor a great body of 
prognostic and predictive information.  
 
 
3. Modeling breast tissue-specific function in three dimensions 
Non-malignant as well as malignant mammary cells typically have been studied as 
monolayer cultures on tissue culture plastic in the absence of proper ECM thereby 
losing their tissue-specific function and morphological organization [36]. It is, 
therefore, not surprising that many aspects of the complex mammary biology and 
tumorigenesis are still not fully understood. Three-dimensional culture systems allow 
cells to organize into structures that mimic their in vivo architecture and to investigate 
gene functions and signaling pathways in a physiologically relevant context. 
The most prominent change in the cellular composition of the mammary gland which 
accompanies the conversion of non-malignant epithelial cells to malignant tumors is 
the disappearance of myoepithelial cells, the increase in myofibroblasts in the stroma 
and enhanced vascularization [37-40]. More recently there is increased recognition 
that the immune cells also arrive at the scene and that they play a crucial role in the 
disruption of the 3D architecture and function [41,42].  
 
3.1. 3D culture models of human mammary cells 
Besides providing structural support, the BM has been shown to be critical in 
regulating proliferation, organization and differentiation of the breast tissue [1,43]. 
The BM is a specialized form of ECM, and is composed mainly of laminin and type 
IV collagen (for review see [44]). By embedding cells in a 3D environment of lrECM, 
 
many aspects of the morphology and functions seen in vivo can be restored in culture 
[9-11,45]. Normal mammary epithelial cells and non-malignant cell lines form 
polarized spheroids (‘acini’) with a central lumen when grown in 3D lrECM 
resembling the normal mammary gland acinus [10,11] (Fig. 1B). Remarkably, murine 
mammary epithelial cells cultured in 3D gels even respond to lactogenic hormones by 
producing and secreting milk proteins [8,10,45,46].  
These data make it increasingly clear that 3D cultures can promote expression of 
tissue-specific functions by allowing cells to receive cues from their neighboring cells 
and the BM, which cannot be achieved when cells are plated on tissue culture plastic 
or other 2D substrata.  
These 3D models do not only allow the study of non-malignant mammary cells but 
also of breast cancer cells in the more appropriate context. Morphologically, normal 
and malignant breast cells are indistinguishable when grown as monolayers (Fig. 1B). 
However, when cultured in a 3D lrECM, tumorigenic mammary cells can easily be 
discriminated from normal or non-malignant cells: instead of forming polarized acinar 
structures as they arrest growth [10], cancer cells continue to proliferate and form 
disorganized tumor-like structures [11,47,48] (Fig. 1B). The morphological 
differences observed between normal S1 and malignant T4-2 breast cells have been 
demonstrated to be due to aberrant integrin and growth-factor-receptor pathway 
activation in the cancer cells. The inhibition of either the β1-integrin, EGFR signaling, 
or related down-stream signaling pathways (MAPK and PI3K) causes disorganized 
tumor cells to functionally and morphologically revert to growth-arrested acini, 
despite their malignant genotype [49-51](Fig. 1B). The attenuation of the aberrant 
signaling pathways in cancer cells grown in 3D lrECM also led to normalization of 
key signaling protein expression levels to those present in normal cells, a feedback 
inhibition that did not occur in 2D cultures [50,52]. This reversion assay illustrates 
that signaling pathways are dramatically different in their regulation and integration 
when cells are propagated in a 3D environment [43,53]. 
Additional proteins have been identified to be central regulators of breast acinar 
architecture. Using these models, inhibition of the small GTPase Rap1 in T4-2 breast 
cancer cells was shown to restore the tissue polarity of the normal acinar architecture 
and reduced tumorigenicity of these cells [54]. In line with this, the re-expression of 
genes frequently lost in breast cancer, such as α-dystroglycan (α-DG), the 
 
carcinembryonic antigen-related cell adhesion molecule (CEACAM1), or the gap 
junction proteins hCx43 and hCx26, have been shown to allow breast cancer cells to 
form normal acinar-like structures in 3D cultures [55-57]. In contrast, the introduction 
of oncogenes or activated growth factor receptors into non-transformed mammary 
MCF10A cells, which form polarized acini when grown on 3D lrECM, altered acinar 
morphogenesis [58-60]. Interestingly, the multi-acinar phenotype induced by ERBB2 
in MCF10A in 3D culture shows great similarities with human ERBB2 amplified 
DCIS lesions [58].  
 
The integrity and polarity of epithelial cells is important for the expression of 
membrane receptors, such as coxsackie adenovirus receptor (CAR) [61]. When 
comparing CAR expression in normal mammary epithelial and spontaneous 
tumorigenic cells derived from a human breast cancer progression series [47,62,63], 
no difference in CAR protein levels were found when the cells were grown in 2D. In 
contrast, CAR protein expression was significantly reduced in non-malignant cells 
compared to malignant cells when grown in 3D [61]. Such observations indicate that 
the study of architecturally organized cells might help to identify previously unknown 
functions of genes or pathways. The activity of polo-like kinase 1, for example, which 
promotes the progression of cells through mitosis [64], was recently shown in our 
laboratory to be required for invasiveness of vimentin expressing cells [65].  
Altogether, these data demonstrate convincingly that 3D culture models provide a 
physiologically relevant approach to dissect molecular mechanism and signaling 
pathways in mammary epithelial cells ex vivo. 
 
3.2. 3D models for breast cancer research and treatment 
Cell lines derived from human primary tumors or metastases have been extensively 
used for the ex vivo and in vivo study of breast cancers. Because of the molecular 
heterogeneity of the disease, no individual cell line holds all the genomic and 
transcriptional abnormalities detected in human breast carcinomas, but it has been 
repeatedly shown that a panel of cell lines may indeed represent the spectrum of the 
different breast cancers [66-68]. Keeping this in mind, these studies resulted in the 
identification of biomarkers for prognosis as well as an overwhelming number of 
potential drug targets. However, only very few of these novel molecular markers and 
targets are translated into clinical practice. To improve the success rate of the 
 
implementation of biomarkers and the development of candidate drugs, and to 
identify those breast cancer patients who may benefit most from a certain type of 
treatment, human tissue surrogates are needed. Three-dimensional culture systems, 
such as those used for the study of normal mammary epithelial cells, might be a well 
suited approach for predictive drug response screens and might guide patient selection 
for clinical trials.  
In an attempt to overcome drug resistance and to augment the efficacy of breast 
cancer treatment, the combination of drugs, in particular of targeted therapeutics and 
cytotoxic agents, is currently explored ([69] and therein). The number of rational drug 
combinations is, however, too large for testing in clinical trials. Here also, 3D culture 
models provide an appropriate system for studying combination therapies in an in 
vivo-like environment to identify the most efficacious treatments.  
 
Our proposition is supported by data that not only non-malignant mammary cells 
show a difference in their gene and protein expression depending on the nature of the 
substrata but also breast cancer cell lines, which are less sensitive to environmental 
perturbations, show significant differences in signal transduction genes when cultured 
in 3D environments [61,70]. Whereas a panel of 25 breast cancer cell lines was 
observed to form indistinctive monolayers when grown on 2D cultures, they showed 
characteristic morphologies when cultured on 3D lrECM (Fig. 2). These 3D 
morphologies have been categorized into four classes, referred to as Round, Mass, 
Stellate and Grape-like [70] (Fig. 2). The 3D morphological classes in turn correlated 
well with the underlying gene expression patterns and functions. The cell lines that 
fell into the ‘Stellate’ 3D morphology, for example, all lack E-cadherin, whereas the 
ones with ‘Grape-like’ morphology have elevated levels of HER2 [70], suggesting 
that the 3D morphology can also serve as a read-out for the behavior and function of 
carcinoma cells.  
In addition, the 3D tissue architecture itself has been found to be fundamental to the 
behavior of cancer cells. When grown on tissue culture plastic, both non-malignant 
and malignant breast cells exhibited comparable sensitivity to apoptosis induced by 
different agents used for therapy of breast and other types of cancer [71]. When 
embedded in 3D lrECM, however, only the malignant cells were sensitive to 
apoptosis induction, whereas the non-malignant cells forming acini were resistant. 
When reverting the malignant cells from disorganized to polarized structures, they 
 
also showed apoptosis resistance in response to the chemotherapeutic agents tested. 
Interestingly, in a 3D microenvironment it is the correct polarization of the acini- 
irrespective of the genetic make-up or growth rate of the non-malignant and the 
reverted malignant cells that accounts for resistance to apoptosis. This observation 
was traced to hemidesmosome formation, β4-integrin ligation and NFκB activation in 
the polarized structures [71]. In similar veins, the breast cancer cell line, MCF7, has 
been shown to be less responsive to the anti-estrogen tamoxifen when cultured on a 
3D chitosan polymer scaffold compared to MCF7 cells grown on tissue culture plastic 
[72]. At a tamoxifen concentration of 10(-6) M, there was a 50% growth inhibition of 
MCF7 cells in 2D, but only 25% in 3D cultures. The differential response was caused 
by a higher level of lactate production of MCF7 cells similar to that observed for 
tumor cells in vivo when grown in 3D compared to culture plastic [72]. This most 
probably reflects lower level of glucose uptake by transformed cells in 3D versus 2D 
[73]. These findings emphasize the importance of studying also cancer cell signaling 
or drug response when they form tumor-like structures rather than when they are on a 
flat monolayer.  
 
As discussed earlier in this review, tissue organization and proliferation are the 
striking observable differences between non-malignant and their malignant 
counterparts. The proof of principle has been convincingly tested by analyzing the 
transition of non-malignant breast epithelial cells from a disorganized, proliferating 
state to an organized growth-arrested state in 3D lrECM [74]. Microarray analysis of 
unpolarized dividing versus polarized acinus-like structures of two non-malignant 
mammary epithelial cell lines identified, as expected, a set of differentially expressed 
cell cycle and cell division genes. Importantly, those genes that were significantly 
down-regulated in the organized growth arrested acini beyond the proliferating cells, 
had prognostic value and could be applied to accurately discriminate between breast 
cancer patients with poor and good outcome [74].  
 
Gene expression profiling of human breast tumors has been a powerful tool in the 
identification of molecular signatures predicting outcome in breast cancer patients 
more precisely than standard clinical and histological markers [31,75-77]. The 
discovery of expression profiles predicting drug response, however, remains a 
challenge and strongly depends on the study design, the drugs used, and the number 
 
of patients included. As a consequence, only a few studies have been able to identify 
clinically meaningful predictors to assign which individual patient is likely to benefit 
from a certain chemotherapeutic regimen [78,79]. In addition to primary tumor 
materials, cell lines cultured as 2D monolayers have been used to establish predictive 
response patterns [80,81]. The study of breast cancer cell lines in 3D culture models 
might generate even more powerful therapy response predictors, since the 3D 
architecture of tumor cells has been shown to have great impact on drug resistance 
[71]. 
 
While 3D lrECM cell culture models harbor great potential for the discovery of novel 
biomarkers, they also can be employed for functional studies of candidate genes or 
proteins and for the validation of potential breast cancer targets. The latter has been 
reported for two prospective drug targets, β1-integrin and tumor necrosis factor α-
converting enzyme (TACE/ADAM17). The cell surface receptor β1-integrin mediates 
cell-extracellular matrix interactions [82]. This receptor has been recognized to play a 
role in invasion and metastasis [83,84], and increased β1-integrin expression has been 
correlated with poor survival in breast cancer patients [85]. In addition, and as 
illustrated earlier in this review, down-modulation of β1-integrin signaling in breast 
cancer cells results in reversion of the malignant phenotype by inducing growth arrest 
and restoration of tissue polarity when propagated in a 3D context [49,86]. Addition 
of β1-integrin inhibitory antibody, AIIB2, to already formed tumor colonies of several 
different breast cancer cell lines cultured on top of 3D lrECM gels resulted in a 
significant decrease in cell numbers and proliferation, and an increase in apoptosis 
[87]. In contrast, the acinar structures formed by non-malignant mammary epithelial 
cells did not respond to the antibody, again indicating the utility of 3D culture assays 
to discriminate non-malignant and malignant cell response to therapeutic agents [71]. 
Both observations could be confirmed in vivo: AIIB2 inhibited breast tumor growth in 
nude mice as a result of anti-proliferative and pro-apoptotic effects, whereas 
importantly no recognizable toxicity to the host could be observed [87].  
Similarly, TACE, a metalloproteinase, has emerged as a new therapeutic target in 
cancer [88]. TACE has been shown to be responsible for the shedding of several 
EGFR ligands, such as TGF-α and amphiregulin, which in turn bind and activate the 
receptor tyrosine kinase EGFR [89]. In breast cancer, EGFR is frequently 
 
overexpressed, leading to an increased down-stream signaling, which has been 
implicated in cancer development and progression [90-92]. One strategy to inhibit 
receptor function is the use of small molecule tyrosine kinase inhibitors, binding to 
the ATP binding site of the tyrosine kinase domain of the receptor. Alternatively, 
EGFR signaling in breast cancer can be inhibited by blocking the activity of TACE, 
which regulates the bioavailability of EGFR ligands. The breast cancer cell line T4-2 
has been found to be dependent on the activity of the EGFR pathway and to 
overexpress the EGFR ligands amphiregulin and TGF-α [93]. Comparable to the 
effects seen when targeting EGFR signaling, treatment of T4-2 cells grown in 3D 
lrECM with a small molecule inhibitor of TACE, TAPI-2, resulted in the reversion of 
the malignant phenotype of T4-2 cells into phenotypically normal mammary acinus-
like architectures. The TACE-dependent shedding of amphiregulin and TGF-α was 
observed also in a number of additional breast cancer cells lines, and could be 
inhibited by TAPI-2 treatment, hence leading to down-regulation of MAPK activity 
[93]. These findings suggest that besides targeting EGFR directly, the attenuation of 
the autocrine activation of EGFR by inhibiting TACE might be an effective therapy 
for tumors of the breast and other tissues such as lung, which are driven by EGFR 
signaling.  
Collectively, these studies emphasize the value of 3D models over conventional cell 
culture approaches in the study of breast cancer as they harbor great potential for the 
implementation of therapeutic screening and drug target validation. 
 
 
4. What will the future bring? 
 
4.1. Development of heterotypic 3D cell culture models  
Three-dimensional models such as those described in this review represent a proof of 
principle: by allowing tissue organization and BM signaling they mimic the 
phenotypic and morphological behavior of cells in vivo and better delineate normal 
from malignant cells than conventional tissue culture models. To even more faithfully 
resemble the histological complexity of the normal breast and breast cancers, and to 
help fill the remaining gap between cell culture and whole-animal systems, more 
intricate 3D models are required. This is because in addition to receiving cues from 
the microenvironment, the behavior of normal and malignant mammary cells is 
 
regulated by neighboring cells, stromal cells, soluble factors and physical forces 
[41,94]. 
The lrECM matrix currently used for 3D cell culture is extracted from a BM 
producing mouse tumor [10]. As with all natural products, this results in variations in 
the composition of ECM proteins and growth factors as well as the mechanical 
properties of the gels. This variation can challenge the reproducibility of experimental 
findings and the unraveling of the roles of specific ECM factors [95]. Synthetic 
scaffolds, however, provide well-defined and reproducible extracellular environments 
and have great potential for the study of complex physiological processes like breast 
tumorigenesis in culture [95-98]. These synthetic ECMs constitute the ideal 
foundation for building functional breast tissues ex vivo including multiple cell types. 
 
Even though it is known that the ductal-lobular system of the normal breast comprises 
a double-layered structure of inner luminal epithelial cells and outer myoepithelial 
cells, research has been focused mainly on luminal epithelial cells only. This is 
probably due to the fact that most breast carcinomas are thought to be of a luminal 
origin. Only recently, myoepithelial cells have gained increased attention due to their 
proposed natural tumor suppressive function [99,100]. A first step towards building a 
heterotypic breast cell model is the introduction of myoepithelial cells in the cell 
culture systems. It has been shown that the bilayered acinar structures can be 
recapitulated in 3D models by co-culturing luminal epithelial cells and myoepithelial 
cells [100,101]. Interestingly, unlike normal myoepithelial cells, tumor-derived 
myoepithelial cells appear to have lost their ability to confer correct polarity to 
epithelial cells, the crucial organizing principle in the mammary gland [43]. In vivo, 
normal myoepithelial cells produce laminin-1, a feature these cells might lose during 
malignant transformation. Thus, the inability of the ‘tumor myoepithelial cells’ to 
correct inside-out acini of normal epithelial cells in collagen gels is due to their low or 
non-functional laminin-1 expression [100] (Fig. 3). 
Epithelial cells interact also via paracrine signaling with the adjacent stromal cells 
[102-105]. Fibroblasts are the major cell type of the stromal compartment and since 
the myoepithelial cells are largely lost in breast cancer, it has become apparent that 
breast cancer progression is largely influenced by the cross-talk between the epithelial 
tumor cells and stromal fibroblasts (for reviews see [106-108]). The importance of the 
paracrine functions of fibroblasts was illustrated by a gene expression signature of the 
 
response of fibroblasts to serum, which by itself was effective in accurately predicting 
metastasis and death in several different carcinomas, but especially in breast cancer 
[109,110]. Even though cancer-associated fibroblasts (CAF) have been identified as 
key determinants in the malignant progression of breast cancer, only few studies 
report the co-culture of epithelial cells and fibroblasts in 3D environments. Co-
cultivation of normal reduction mammoplasty fibroblasts or CAFs with the non-
malignant mammary epithelial cell line MCF10A on a reconstituted BM has been 
shown to result in suppressed epithelial cell proliferation, whereas in co-culture with 
the transformed MCF10AT cell line, only the normal breast-associated fibroblasts had 
an inhibitory effect on MFC10AT cell growth [111]. Similarly, the cultivation of 
primary breast tumor cells with a mix of fibroblasts, vascular smooth muscle cells and 
pericytes in 3D collagen gels caused the tumor cells to spread and become invasive 
[112]. This effect on the breast carcinoma cells could be enhanced with greater 
concentrations of the stromal cells. Interestingly, the co-culture of fibroblasts with 
primary breast tumor cells or breast cancer cell lines was already sufficient to form a 
structure of typical breast tumor morphology inside 3D collagen gels [112] and in 
spheroid cultures [113,114].  
An additional stromal cell type that is abundant in the breast is the adipocyte. Co-
cultivating primary non-malignant mammary epithelial cells or breast cancer cells 
with adipocytes in 3D collagen matrices resulted in differentiated epithelial structures 
embedded in nests of adipocytes [115,116]. The structural formation observed closely 
resembled the human breast tissue in vivo. For a long time it was unclear whether 
adipocytes actually affect the behavior of breast carcinoma cells or whether they are 
innocent bystanders. It now has been shown that adipocytes interact with breast 
cancer cells in a paracrine manner and promote the growth of several ER-positive 
breast cancer cells lines but not that of ER-negative cells in the 3D co-culture model 
[116].  
Until now, the heterotypic cell models described in the literature usually only include 
one additional cell type next to normal and malignant mammary epithelial cells. The 
final step towards achieving an engineered mammary gland or breast tumor, however, 
will be the incorporation of all the different stromal cell types, fibroblasts, immune 
cells, endothelial cells and adipocytes, together with epithelial cells in one culture 
model [97]. A major challenge in creating such heterotypic cell system will be the 
different metabolic and nutritional requirements of the different cell types. Culture 
 
conditions will have to be defined in a way that allows each cell type to grow and 
maintain in a differentiated state in combination with the other cell types, which is a 
difficult task. Modeling a normal mammary gland involves an additional challenge 
since only the luminal epithelial and myoepithelial cells are in direct contact but 
physically separated from the stromal cells by the BM. Breast carcinomas on the other 
hand have lost their tissue organization and all cell types are intermingled. However, 
here also one has to act with caution to prevent the rapidly proliferating breast cancer 
cells from overgrowing the other slow cycling cells, such as endothelial cells. Once 
overcoming these obstacles, designing a multicellular normal or cancerous breast ex 
vivo will allow many possibilities to study the heterotypic interactions between 
mammary epithelial or breast cancer cells and normal versus tumor-associated stromal 
cells.  
 
4.2. The tumor microenvironment as drug target 
Even if there is still much left to learn about the heterotypic epithelial-stromal 
interactions in normal and malignant tissues, we now recognized that cancer initiation 
and progression are the result of an evolving cross-talk between epithelial cells and 
the surrounding microenvironment (for reviews see [41,108,117-119]). Besides its 
contribution to tumorigenesis, tumor stroma might also be involved in drug resistance 
by affecting the bioavailability and efficacy of chemotherapeutic agents [120,121]. 
The appreciation of the importance of the microenvironment in cancer has begun to 
result in the development of drugs targeting either the tumor stroma cells or the 
tumor-host signaling processes. However, the perturbation of the tumor 
microenvironment is quite challenging. For example, a drug for systemic use needs to 
selectively target only the stromal component of the tumor and avoid endothelial, 
immune cells or fibroblasts in normal tissues elsewhere in the body. In addition, the 
heterotypic signaling between tumor and stromal cells is complex and balanced 
between pro- and anti-tumorigenic functions, as learned from the matrix 
metalloproteinases (MMPs) inhibitors. MMPs are promising drug targets for various 
cancer types based on their observed up-regulation and ability to remodel the ECM 
during invasion and metastasis (for reviews see [122-124]). The results from clinical 
trials, however, have been disappointing: broad MMP inhibitor treatment did not 
result in survival benefit and patients suffered from unexpected side effects [122]. 
 
This is because MMPs have many other signaling functions outside remodeling the 
tumor ECM including host-protective ones [124,125]. 
 
So far, the most successful therapeutic agents, which target a microenvironmental 
component in breast cancer, are aromatase inhibitors. The third generation inhibitors 
(anastrozole, letrozole and exemestane) effectively reduce the hazard of recurrence 
and have largely replaced tamoxifen in the adjuvant hormonal treatment for ER-
positive breast cancer in postmenopausal women [126]. In contrast to tamoxifen, 
which active metabolites’ bind to the ER and inhibit cell proliferation, aromatase 
inhibitors target aromatase, a key enzyme in the biosynthesis of estradiol from 
androgens. The major producer of estrogen in breast carcinomas are the tumor-
associated stromal cells, but also the cancer cells themselves have been reported to 
have aromatase-activity [127]. 
Another attractive target in the microenvironment is the tumor vasculature [128]. In 
order to grow beyond a certain size, both locally and at distant sites, a tumor has to 
recruit its own blood vessels for nutrient and oxygen supply. Angiogenesis, the 
process of neovascularization, has been repeatedly correlated with disease 
progression. In invasive breast carcinoma, microvessels density has been shown to be 
predictive of metastasis development and survival [129,130], as are the levels of the 
angiogenic growth factor VEGF [131]. A large number of antiangiogenic agents, 
which either target the growth factors or their receptors, have been developed and are 
currently in clinical trials. The humanized monoclonal antibody against the ligand 
VEGF-A, bevacizumab, is from a clinical standpoint the most mature. It is approved 
for the treatment of metastatic colorectal cancer in combination with fluorouracil and 
irinotecan [132]. In breast cancer, bevacizumab monotherapy has only minimal 
activity, however, in combination with capecitabine it has been shown to significantly 
increase the response rates in the metastatic setting [133]. The therapeutic benefit of 
combined antiangiogenic and cytotoxic drugs has been suggested to be due to the 
normalization of the tumor vasculature and the subsequent improved delivery of 
therapeutics [134]. Of note, several established therapies including tamoxifen and 
trastuzumab, a humanized monoclonal antibody against HER2, in addition to their 
specific targets also have antiangiogenic activity [135,136].  
 
 
There are numerous additional chemotherapeutic agents targeting either the breast 
cancer microenvironment or mediators of the tumor-stromal cell signaling in different 
preclinical or clinical stages, such as the nonsteroidal anti-inflammatory COX-2 
inhibitors [137], or a blocking antibody against CSF-1, a chemoattractant for 
macrophages synthesized by cancer cells [138]. However, reviewing all targets and 
drugs under investigation would exceed the scope of this article [139].  
 
So far, the results achieved in trials targeting the tumor microenvironment are 
encouraging but also pose new questions and challenges. Tumor and stroma cells 
form a complex functional entity, and each tumor-associated cell type holds 
sophisticated roles in modulating the epithelial cells. To more successfully translate 
fundamental research findings into therapies in the clinic, a better understanding of 
the pro- and anti-tumorigenic effects of the host-stroma interactions is required and 
subsequently appropriate targets have to be identified. One important lesson is the 
need for an in-depth focus on the heterotypic cell signaling using culture systems with 
different cell types, such as the complex 3D models discussed above. In addition, 
clinical trials over the past years have taught us that the most effective treatments are 
those, which combine targeted therapies with conventional cytotoxic agents. Again, 
the question remains how to combine such treatments optimally. Three-dimensional 
cultures of human breast tumors and other types of tumors have great potential in 
providing answers before proceeding into costly trials.  
 
4.3. Breast tumor heterogeneity and the cancer stem cell as drug target  
Breast cancers are clinically, histologically and molecularly heterogeneous. Not only 
is there a large variation regarding the nature of cell types between cancers, but even 
within a single tumor, a significant heterogeneity in morphology, proliferation, protein 
expression and size of cells and nuclei can be observed [26,29]. Understanding the 
cause of this heterogeneity will be of major importance for future therapeutic 
approaches.  
Breast cancer is thought to initiate from a transforming event in a single cell, which 
subsequently acquires additional genetic changes over time [140,141]. The number of 
genes altered in breast cancer is large [68,142], yet the number of common genes 
mutated in tumors of the same kind but in different patients is rather small [26]. 
Morphogenesis studies using the non-malignant MCF10A cells in 3D culture systems 
 
demonstrated how specific cancer genes, such as Akt or ERBB2, might contribute to 
the phenotypic heterogeneity observed in breast cancer [58,59,143]. However, the 
presence of a given mutation still cannot clearly be connected to a specific 
histological or molecular breast cancer type.  
A key to answering the question of breast cancer heterogeneity will be the 
identification of the cell or cells of origin, which are targets of transforming 
mutations, and additionally, the understanding of the origin of the hierarchy of the 
cells within the mammary gland [144]. It has been shown recently that two different 
populations of human mammary epithelial cells originated from the same patient, one 
of which was more myoepithelial-like than the other, after transformation gave rise to 
tumors of different histology and tumorigenicity when injected into mammary fat 
pads of immunocompromised mice [145]. It has been postulated that a subset of 
mammary stem or progenitor cells are targets of tumor initiating genetic or epigenetic 
events. Depending on the kind of mutations the cells have sustained, these tumor-
initiating cells would then have the ability to self-renew and differentiate accounting 
for the observed heterogeneity in breast cancer. 
In rodents, a single mammary stem cell has been shown to give rise to a functional 
mammary gland [146,147]. Excitingly, the stem cell population in the adult human 
breast also have been identified. These are located within a ductal niche giving rise to 
at least three lineage-restricted cell types outside the stem cell zone [144]. These 
findings may suggest that adult stem cells not only play a role in hematopoeitic 
diseases but also in solid tumors such as breast cancer. A breast cancer subpopulation 
with the cell surface marker expression CD44+CD24-/low has been reported to 
efficiently produce tumors in immunodeficient mice containing again all cell lineages 
of the original carcinoma, whereas even large numbers of CD44-CD24+ cells could 
not [148]. These tumor-initiating cells are frequently referred to as ‘breast cancer stem 
cells’.  
It is, however, still unknown whether transformed normal mammary stem or 
progenitor cells indeed form the origin of breast carcinomas or whether a particular 
subset of tumor cells acquires the capacity to de-differentiate and subsequently obtain 
stem cell-like properties such as self-renewal. Independent of this etiology issue, the 
implications for treatments would be profound if breast cancers would indeed be 
driven by a subpopulation of cells. Current therapies might not target the tumor-
initiating cells effectively, as implied by the large number of patients who develop 
 
metastases after adjuvant chemotherapeutic and/or hormonal treatment [149]. The 
design of therapeutic agents specifically directed against tumor-initiating cells would 
theoretically result in a complete response, and if detected at early stage, would turn 
cancer into a curable disease limited to the primary organ. Could cancer stem cells 
represent druggable targets? At this time, we know far too little about the molecular 
features distinguishing a tumor-initiating cell from the bulk of tumor cells in order to 
be able to develop a smart drug. In addition, ATP binding cassette drug transporters, 
which are a major determinant in the resistance to chemotherapeutics, play a crucial 
role in the regulation of normal stem cells [150]. If cancer stem cells retain this 
feature, they will be challenging to treat. 
Again, we are faced with the question of the cell of origin. Is there only one uniform 
breast tumor-initiating cell or are we faced with heterogeneity at even the earliest 
stages? It has been suggested that the specialized microenvironment of the stem and 
progenitor cells, i.e. the niche, directs the behavior of this cell population [151,152]. 
The microenvironmental composition of the niche as well as the environmental and/or 
genetic changes leading to aberrant heterotypic signaling events could result in 
differences in the molecular make-up of the tumor-initiating cells in different patients 
from the start.  
Not having a crystal ball, the future will have to tell if these predictions are correct! 
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 Figure legends 
Fig. 1. The normal and malignant breast. (A) Hematoxylin and eosin staining of tissue 
sections from a normal adult breast and an invasive ductal carcinoma. The normal 
mammary gland is a highly organized structure. The acini have a central lumen and 
are lined by an inner layer of luminal epithelial and an outer layer of myoepithelial 
cells. The bi-layer of epithelial cells is separated by a BM from the surrounding 
stroma, which is comprised of stromal ECM and stromal cells such as fibroblasts and 
adipocytes. Breast carcinomas have lost organized tissue architecture. Cancer-
associated fibroblasts are the major cell type of the tumor stroma. (B) Cells from the 
normal and malignant mammary gland form indistinctive monolayers when plated on 
plastic substratum. (left) In 3D lrECM, normal mammary epithelial cells form 
spherical structures with a hollow lumen. (right) Breast cancer cells form disorganized 
tumor-like structures in 3D lrECM, which can be reverted to near-normal morphology 
by normalizing aberrant signaling pathways.  
 
 
Fig. 2. Morphologies of breast cancer cell lines cultured in 2D and 3D. (top) Images 
of 4 representative breast cancer cell lines cultured as 2D monolayer, (middle) and in 
3D lrECM grouped by 3D morphological classification: Round, Mass, Grape-like and 
Stellate. (bottom) 3D cultures were stained for F-actin and nuclei were counterstained 
with DAPI. Scale bars: top panel, 100 µm; middle panel, 50 µm; bottom panel, 20 
µm. Adapted from [70]. 
 
Fig. 3. Myoepithelial cells confer correct polarity to luminal epithelial cells. (a, b, c) 
In lrECM, luminal cells form acini with correct polarity, (a’, b’, c’) whereas in 
collagen I (coll I), they form inside-out acini with reversed polarity. (a’’, b’’, c’’) By 
addition of human myoepithelial cells (MEP) the reversed polarity of luminal cells in 
collagen I is corrected. (a, a’, a’’) Apical marker sialomucin (red) and basal marker 
epithelial specific antigen (green). (b, b’, b’’) Sialomucin (red) and occludin (green), 
which is expressed at apical cell-cell contacts. (c, c’, c’’) nuclear stain (red) and basal 
marker β4-integrin (green). Adapted from [100] with permission of Journal of Cell 
Science. 
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